Scientific deep-dive

Zepbound Maintenance Dose After Goal Weight: SURMOUNT-4 Evidence Review

There is no FDA-approved Zepbound taper after goal weight. SURMOUNT-4 showed roughly half of lost weight returns within 52 weeks of stopping; SURMOUNT-MAINTAIN found a 5 mg step-down keeps most of it. Obesity is a chronic disease, not a finite course.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·8 citations

The honest answer:

There is no FDA-approved dose-tapering protocol for Zepbound after weight goal. SURMOUNT-4 withdrew tirzepatide and patients regained roughly half of their lost weight within a year. Some clinicians keep patients at their highest-tolerated dose; others step down. Long-term GLP-1 therapy is the chronic-disease standard, not a finite course.

At a glance

  • The Zepbound label does not pick one maintenance dose. Section 2 of the prescribing information names three maintenance doses — 5 mg, 10 mg, and 15 mg weekly — and says: “Consider treatment response and tolerability when selecting the maintenance dosage”[4]. There is no tapering schedule and no post-goal protocol.
  • SURMOUNT-4 is the only randomized withdrawal trial. 670 adults lost a mean 20.9% over a 36-week tirzepatide lead-in. Randomized to continue tirzepatide or switch to placebo for 52 more weeks: the continued arm lost an additional 5.5%; the placebo arm regained 14.0% of body weight, leaving them 9.9% below baseline — roughly half of what they had lost[2].
  • STEP-4 found the same pattern for semaglutide. After a 20-week semaglutide 2.4 mg lead-in (mean −10.6%), continuing patients lost an additional 7.9% over 48 weeks while patients switched to placebo regained 6.9%[3]. The class behavior is consistent.
  • A 5 mg step-down now has one randomized trial behind it. In SURMOUNT-MAINTAIN, people who dropped from 10 or 15 mg to 5 mg ended at −16.6% from baseline, versus −21.9% at the full dose and −9.9% on placebo[8]. Intermediate step-downs (to 10 mg or 7.5 mg) are still untested.
  • The cost gap between tiers is real. LillyDirect self-pay vials are $299/mo at 2.5 mg, $399/mo at 5 mg, and $449/mo at 7.5–15 mg on Lilly's refill program ($499 at 7.5 mg and $699 at 10–15 mg at the regular price)[7]. A step-down to 5 mg saves about $600 per year on the refill program, or up to $3,600 per year at the regular price, if it holds weight stable.
  • Obesity is a chronic disease, per the AMA (2013) and AACE/ACE (2016). The framing matters: the question is not when do I stop the drug, but what is the lowest effective long-term dose [5] [6].

What does "maintenance dose" actually mean on Zepbound?

Most patients reading this article use the phrase maintenance dose to mean "the dose I take after I hit my goal weight." The Zepbound FDA labeling uses the phrase differently. In Section 2 of the prescribing information, maintenance doses are the three approved ongoing doses — 5 mg, 10 mg, or 15 mg once weekly — that the patient holds after the titration ramp (2.5 mg for 4 weeks, then 5 mg, then 2.5 mg steps at 4-week intervals to a maintenance dose)[4]. The label says, “Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage”[4]; it does not define a separate post-goal maintenance dose. There is no taper protocol, no step-down algorithm, and no goal-weight stop rule in the Zepbound label.

This matters because patient and prescriber expectations often diverge. Patients arrive at goal weight expecting a structured wind-down. The label expects continued therapy. The two pivotal questions — do I stay at my current dose? and do I stop entirely? — are not addressed by the FDA label. Both have to be answered from the SURMOUNT-4 withdrawal data, cross-class STEP-4 evidence, the chronic-disease framing, and individual prescriber judgment.

For the broader decision tree of what to do at goal — stay, space, microdose, or taper — see our life-after-GLP-1 decision hub. This article focuses specifically on the Zepbound dose question.

SURMOUNT-4: what happens when you stop

SURMOUNT-4[2] is the only randomized withdrawal trial of tirzepatide for obesity. 670 adults with BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity), without type 2 diabetes, completed a 36-week open-label lead-in on tirzepatide titrated to their maximum tolerated dose (10 or 15 mg). The mean weight loss at the end of lead-in was −20.9%. Patients were then randomized 1:1 to continue tirzepatide or switch to placebo for an additional 52 weeks while continuing diet and physical activity counseling.

Trial armLead-in (weeks 0–36)Randomization (weeks 36–88)Total change at week 88
Continued tirzepatide−20.9% TBWLAdditional −5.5% TBWL−25.3% from baseline
Switched to placebo−20.9% TBWL+14.0% body weight regained−9.9% from baseline

The placebo arm regained roughly half of its lost weight (14.0% of body weight) within one year of withdrawal. Importantly, regain was not back to baseline — the discontinued arm held a net −9.9% versus pre-treatment[2], meaningfully better than diet-and-physical-activity counseling alone (placebo arm in SURMOUNT-1 reached −3.1% at 72 weeks)[1]. Stopping is not equivalent to never starting. But for a patient whose goal weight is at −20%, returning to −10% within a year typically means crossing back into overweight or obese BMI ranges, with the metabolic consequences that follow.

Magnitude comparison

SURMOUNT-4 randomized withdrawal endpoints. After a 36-week tirzepatide lead-in producing 20.9% mean weight loss, patients who continued tirzepatide for an additional 52 weeks lost a further 5.5% (net 25.3% from baseline). Patients switched to placebo regained 14.0% (net 9.9% from baseline) — roughly half of the lost weight returned. STEP-4 shows the same pattern with semaglutide 2.4 mg.[2][3]

  • SURMOUNT-4 — continued tirzepatide (net 88 wk)25.3 % TBWL
    additional 5.5% lost after lead-in
  • SURMOUNT-4 — switched to placebo (net 88 wk)9.9 % TBWL
    regained 14.0% from post-lead-in nadir
  • STEP-4 — continued semaglutide (net 68 wk)17.4 % TBWL
    additional 7.9% lost after lead-in
  • STEP-4 — switched to placebo (net 68 wk)5.0 % TBWL
    regained 6.9% from post-lead-in nadir
  • SURMOUNT-1 — diet + physical activity only (72 wk)3.1 % TBWL
    the floor without medication
SURMOUNT-4 randomized withdrawal endpoints. After a 36-week tirzepatide lead-in producing 20.9% mean weight loss, patients who continued tirzepatide for an additional 52 weeks lost a further 5.5% (net 25.3% from baseline). Patients switched to placebo regained 14.0% (net 9.9% from baseline) — roughly half of the lost weight returned. STEP-4 shows the same pattern with semaglutide 2.4 mg.

For the broader regain dynamics across the GLP-1 class, see our GLP-1 stopping and rebound evidence review. SURMOUNT-4 and STEP-4 are the two highest-quality datasets and both point the same direction.

STEP-4: the semaglutide analog confirms the class behavior

STEP-4[3] tested the same continue-vs-withdraw design with semaglutide 2.4 mg. 803 adults with BMI ≥ 30 (or ≥ 27 with a comorbidity), without diabetes, completed a 20-week run-in titrating to the 2.4 mg maintenance dose and reached mean −10.6% body weight loss. Patients were then randomized 2:1 to continue semaglutide or switch to placebo for 48 more weeks.

  • Continued semaglutide: additional −7.9% TBWL over weeks 20–68 — net −17.4% from baseline.
  • Switched to placebo: +6.9% body weight regained over weeks 20–68 — net −5.0% from baseline (about two-thirds of lost weight returned).

The proportional regain — roughly half to two-thirds of lost weight within a year — is similar on both molecules. This is not an idiosyncrasy of tirzepatide or semaglutide individually. It is the GLP-1 class behavior: the drug suppresses appetite and slows gastric emptying for as long as it is dosed; once it is gone, the biology that produced obesity in the first place is still there. For the cross-class comparison with the head-to-head SURMOUNT-5 data, see our tirzepatide vs semaglutide review.

Step-down vs stay-at-max: what the trials now show

SURMOUNT-4 tested only continue at the maintenance dose versus complete withdrawal. The step-down question now has one randomized answer: SURMOUNT-MAINTAIN (Horn, Lancet 2026). After 60 weeks at the maximum tolerated dose (10 or 15 mg), 378 adults were randomized 3:3:2 to stay at that dose, step down to 5 mg, or switch to placebo for 52 weeks. At week 112, weight change from baseline was −21.9% at the full dose, −16.6% at 5 mg, and −9.9% on placebo. The authors called the 5 mg step-down “a valuable alternative to discontinuation”, noting that individual responses varied[8]. Intermediate step-downs (15 mg to 10 mg or 7.5 mg) have still not been tested in a randomized trial, so that part of the evidence base remains clinical experience and dose-response extrapolation. For the full SURMOUNT-MAINTAIN breakdown, see weight regain after stopping tirzepatide.

What we can say from the SURMOUNT-1 dose-response[1]:

  • 5 mg: mean −15.0% TBWL at 72 weeks. The lowest approved maintenance dose still produced clinically meaningful weight loss.
  • 10 mg: mean −19.5% TBWL.
  • 15 mg: mean −20.9% TBWL.

The 5 mg-to-15 mg gradient at the population level is roughly linear-but-compressed: each 5 mg increment adds 4–5 percentage points to the lead-in TBWL, with the top step (10→15 mg) adding only about 1.4 points. The reverse inference is what step-down dosing relies on: if 5 mg was sufficient to achieve −15% from baseline, it is plausible that 5 mg can maintain a similar level post-goal. SURMOUNT-4 did not test this; SURMOUNT-MAINTAIN did, and 5 mg held most but not all of the loss (see above)[8]. The closest data point is that any continued tirzepatide dose in SURMOUNT-4 prevented regain — the trial allowed patients to maintain whatever dose they had escalated to during lead-in (10 or 15 mg), not a stepped-down dose.

In practice, prescribers who step down typically do it for one of three reasons:

  1. Side-effect tolerance. A patient who tolerated 15 mg through the loss phase but has persistent GI symptoms may benefit from dropping to 10 mg or 5 mg post-goal (7.5 mg is a titration step, not a labeled maintenance dose). Symptom relief is the primary endpoint; weight stability is a secondary check.
  2. Cost. The LillyDirect Self Pay tier structure creates real annual savings at lower doses (see the cost section below).
  3. Insurance step-edit pressure. Some payers reauthorize ongoing coverage only at lower doses or require documentation of a maintenance attempt at a lower dose before re-approving 15 mg.

Prescribers who keep patients at the highest-tolerated dose can point to SURMOUNT-MAINTAIN, where the full dose held about 5 percentage points more weight off than 5 mg[8]. Neither approach is wrong; both are clinical judgments outside the FDA label.

Why obesity treatment is chronic, not a "course"

This is the most important section of the article because it reframes the entire question. Patients commonly ask when can I stop the medication? — the same way they would ask about a course of antibiotics or a steroid taper. That framing is wrong, and reframing it explicitly changes the answer.

The American Medical Association formally recognized obesity as a disease in June 2013 (Resolution 420, Policy H-440.842) [5]. The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology have published comprehensive clinical practice guidelines treating obesity as a chronic disease since 2014, with the 2016 update[6] stating explicitly that pharmacotherapy for obesity is intended to be a chronic long-term therapy, analogous to the way hypertension is managed with long-term antihypertensives or hypothyroidism with long-term levothyroxine.

The biology supports this. The mechanism by which tirzepatide produces weight loss — GIP and GLP-1 receptor agonism slowing gastric emptying, reducing food intake, and signaling satiety — is active for as long as the drug is dosed. When the drug is withdrawn, the receptor signal stops and the biology that produced the original obese phenotype reasserts. SURMOUNT-4 documented this mechanistically: appetite returned, caloric intake increased, and weight regain followed within weeks of the placebo switch[2].

The clinical analogies are intentional and load-bearing:

  • A patient does not finish a course of lisinopril after blood pressure normalizes. They stay on it because stopping returns blood pressure to baseline. Obesity therapy works the same way.
  • A patient does not finish a course of metformin or insulin after blood sugar normalizes. They titrate to the lowest effective dose and continue indefinitely.
  • A patient does not finish a course of statin therapy after LDL cholesterol normalizes. Discontinuation reverses the gains.

The question that flows from this framing is not when do I stop Zepbound? — it is what is the lowest effective long-term dose, and how do I keep continuous access to it?

Cost trade-offs at each Zepbound dose tier

The 2026 LillyDirect Self Pay program for Zepbound single-dose vials is tiered by strength[7]. The gap between tiers is modest on Lilly's refill program and wide at the regular price, and it is one of the legitimate reasons a step-down may make sense for cost-stable patients who are post-goal.

Zepbound doseLillyDirect self-pay (refill program / regular)Annual cost (refill program, held year-round)Savings vs 15 mg/year (refill program / regular)
2.5 mg (starter only)$299 / $299$3,588$1,800 / $4,800
5 mg$399 / $399$4,788$600 / $3,600
7.5 mg$449 / $499$5,388$0 / $2,400
10 mg$449 / $699$5,388$0 / $0
12.5 mg$449 / $699$5,388$0 / $0
15 mg (maximum)$449 / $699$5,388baseline

On the refill program, stepping from 15 mg down to 7.5 mg saves nothing (both are $449/mo), while stepping to 5 mg saves about $600/year. At the regular price the gaps widen: about $2,400/year for 7.5 mg and $3,600/year for 5 mg. If insurance covers the drug at any dose, the calculation collapses and the clinical question dominates. For patients on self-pay or with high deductibles, the dose tier is a real component of the decision. For a personalized estimate, our GLP-1 savings calculator walks through the math at each tier.

Compounded tirzepatide ($200–$300/mo range in 2026) is the cheaper but regulatorily gray-zone option — the FDA enforcement-discretion period for tirzepatide compounding ended in October 2024, and ongoing 503A activity sits outside the FDA-approved supply chain. The brand-name LillyDirect channel is the cleaner option for post-goal maintenance if cost permits. For an alternatives view if Zepbound itself is the constraint, see our Wegovy and Zepbound alternatives review.

How prescribers handle the goal-weight decision in 2026

There is no single "right" answer because the prescribing information leaves the decision to the prescriber. Across the obesity-medicine specialists tracking this question in 2026, four post-goal patterns recur:

PatternWhat it looks likeEvidence anchorWhen it fits
Stay at the highest-tolerated doseContinue 15 mg (or 10 mg if that was the maximum tolerated) indefinitely; reassess only if side effects appearSURMOUNT-4 continue arm: additional −5.5% over 52 weeks; zero regain[2]First 12–18 months post-goal; insurance-covered; well-tolerated
Step down to next-lower tier15 mg → 10 mg, or 10 mg → 5 mg, after a stable goal-weight window of 3–6 months (the labeled maintenance doses are 5, 10, and 15 mg)SURMOUNT-1 dose-response[1]: 10 mg still produced −19.5% TBWL; extrapolation, not RCTCost-sensitive; persistent GI side effects; insurance step edits; stable weight for 6+ months
Step down to lowest maintenance dose (5 mg)Drop to 5 mg as a long-term "floor" after 12+ months of stable goal weightSURMOUNT-1 5 mg arm[1]: −15.0% TBWL at 72 weeks — sufficient to achieve, but maintenance-only data are absentCost-driven; stable weight for 12+ months; high adherence; patient preference for minimal drug exposure
Extended-interval same dose (off-label spacing)15 mg every 10–14 days instead of weekly; no FDA support, occasionally seenNone — not studied in any randomized trialPatient experimentation; not a guideline-supported approach; full taper or 5 mg weekly preferred

Two cross-cutting principles show up in essentially every clinical framework:

  1. Reassess every visit. Weight, blood pressure, A1c, side effects, lipid panel. A step-down that holds for 6 months is a success; a step-down that lets weight drift back 1–2% is the signal to step back up.
  2. Never "just stop" without a plan. SURMOUNT-4 documented that "simply stop" brings back roughly half of lost weight within a year, and SURMOUNT-MAINTAIN showed a 5 mg step-down keeps much more of it[8]. If full discontinuation is the goal — pregnancy planning, surgical preparation, intolerable side effect, patient preference — build a structured bridge with intensified lifestyle support, frequent follow-up, and a low threshold to restart. For the broader stop/taper discussion, see our GLP-1 stopping evidence review.

Patients at goal should be tracking the brand under their drug page — Zepbound — for updated FDA labeling and supply information that affects long-term maintenance decisions.

Verdict

There is no FDA-defined post-goal maintenance protocol for Zepbound. The pivotal randomized evidence — SURMOUNT-4 for tirzepatide and STEP-4 for semaglutide — shows that complete withdrawal brings back roughly half (tirzepatide) to two-thirds (semaglutide) of lost weight within a year. Continued therapy at the highest tolerated dose produces additional weight loss. A step-down to 5 mg was tested in SURMOUNT-MAINTAIN and held most, but not all, of the loss[8]; intermediate step-downs have not been tested in a randomized trial. Obesity is a chronic disease per the AMA (2013) and AACE/ACE (2016); the right framing of the question is what is the lowest effective long-term dose, not when can I stop.

For most patients in the first 12–18 months post-goal, staying at the highest-tolerated dose is the trial-supported default. Cost, side-effect tolerance, and insurance step edits are legitimate reasons to consider a step-down with close follow-up. Stopping cold without a structured bridge plan is the option with the strongest evidence against it.

Further reading

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

The Zepbound FDA label names three maintenance doses — 5 mg, 10 mg, or 15 mg once weekly — and tells the prescriber to consider treatment response and tolerability when selecting one. There is no separate FDA-defined post-goal maintenance dose. SURMOUNT-4 randomized patients who reached 20.9% mean weight loss to either continue their tirzepatide dose or switch to placebo for 52 weeks. Continued patients lost an additional 5.5%; placebo patients regained 14.0% of body weight — roughly half of lost weight. Staying at the highest tolerated dose is the trial-supported default; the 2026 SURMOUNT-MAINTAIN trial found a 5 mg step-down kept most, but not all, of the loss.
Yes, some prescribers step down after a stable goal-weight window, for example from 15 mg to 10 mg or 5 mg (7.5 mg is a titration step, not a labeled maintenance dose). The SURMOUNT-MAINTAIN trial (2026) tested a step-down to 5 mg: people ended 16.6% below baseline, compared with 21.9% for those who stayed at 10 or 15 mg and 9.9% for those switched to placebo. Staying at the highest tolerated dose holds the most weight off; 5 mg holds most of it. Step-downs to 10 mg or 7.5 mg have not been tested in a trial. Reassess at every visit and step back up if weight drifts.
SURMOUNT-4 directly tested this. 670 adults completed a 36-week tirzepatide lead-in (mean 20.9% weight loss) and were randomized to continue tirzepatide or switch to placebo. The placebo arm regained 14.0% body weight in 52 weeks — roughly half of what they had lost. The continued arm lost an additional 5.5%. Stopping Zepbound is not equivalent to never starting (the discontinued arm still held a net 9.9% loss versus baseline) but most of the weight loss is lost within a year of stopping.
Per the American Medical Association (2013 Resolution 420, Policy H-440.842) and the AACE/ACE clinical practice guidelines (2016), obesity is classified as a chronic disease and pharmacotherapy is intended to be long-term. The AACE guidelines explicitly state that obesity pharmacotherapy is intended as chronic long-term therapy. The clinical analogy is hypertension or hypothyroidism — patients do not finish a course of lisinopril or levothyroxine after numbers normalize. The current evidence supports continued therapy as the default.
Through the LillyDirect Self Pay vial program in 2026, Zepbound is priced by strength: $299 per month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg on Lilly's refill program (refill within 45 days); otherwise the regular price is $499 for 7.5 mg and $699 for 10 to 15 mg. On the refill program, annual costs run $4,788 at 5 mg and $5,388 at 7.5 to 15 mg, so a step-down from 15 mg to 5 mg saves about $600 per year; at the regular price the same step-down saves about $3,600 per year. Insurance-covered patients see a different math.
SURMOUNT-4 showed that stopping after 36 weeks brought back roughly half of the lost weight within a year, and only 16.6% kept at least 80% of their loss. It did not test a lower dose; the later SURMOUNT-MAINTAIN trial did, and a 5 mg step-down kept much more weight off than stopping. The strongest evidence in favor of continued therapy is SURMOUNT-4 plus the AMA/AACE chronic-disease framing; the strongest evidence against full discontinuation is the same trial. Extended intervals and structured tapers are still outside the trial evidence base.
Yes. STEP-4 tested the same continue-vs-withdraw design with semaglutide 2.4 mg. After a 20-week run-in (mean 10.6% weight loss), continued patients lost an additional 7.9% while patients switched to placebo regained 6.9% — about two-thirds of lost weight. The proportional regain is the same on both molecules. This is a GLP-1 class behavior, not a tirzepatide-specific finding.
SURMOUNT-1 showed that 5 mg tirzepatide produced 15.0% mean weight loss over 72 weeks — sufficient to achieve substantial weight loss. Whether 5 mg can maintain a 20% loss already achieved at 15 mg has not been tested in a randomized trial. The biologic plausibility is real; the RCT data is absent. Patients and prescribers who go to 5 mg post-goal are operating on dose-response extrapolation and should track weight closely, with a low threshold to step back up if drift appears.
Continuing a maintenance dose is what prevents regain, because obesity is a chronic condition rather than a finite course. In SURMOUNT-4, patients who kept taking tirzepatide held their loss and shed a further 5.5%, while those switched to placebo regained about 14.0% of body weight — roughly half of what they had lost. There is no single fixed maintenance dose: many people stay on whatever dose controlled their weight (commonly 5, 10, or 15 mg once weekly), and some clinicians trial the lowest effective dose. Stopping tends to bring appetite and weight back, so the ongoing dose is individualized with your prescriber.

References

  1. 1.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  2. 2.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
  3. 3.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. 5.American Medical Association House of Delegates. Resolution 420 (A-13): Recognition of Obesity as a Disease (Policy H-440.842). AMA Policy Finder. 2013. https://policysearch.ama-assn.org/policyfinder/detail/H-440.842
  6. 6.Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016. PMID: 27219496.
  7. 7.Eli Lilly and Company. LillyDirect Self Pay — Zepbound single-dose vials by strength. lilly.com/self-pay. 2026. https://www.lilly.com/self-pay
  8. 8.Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. PMID: 42119587.

Ozempic Snap Back: Anti-Rebound TikTok Term and the Real Evidence

"Ozempic snap back" is TikTok shorthand for rapid weight regain after stopping. STEP-4 and SURMOUNT-4 randomized trials show patients regain roughly half to two-thirds of lost weight within about a year. Obesity is a chronic disease — long-term GLP-1 therapy is the standard.

14 min read

Stopping Wegovy / Zepbound / Ozempic: Rebound Weight Gain Evidence and Transition Planning

Stopping a GLP-1 usually means regaining much of the weight. After stopping semaglutide in STEP-4, weight rose 6.9% from the week-20 weight over 48 weeks; after stopping tirzepatide in SURMOUNT-4, it rose 14.0% from the week-36 weight over 52 weeks, and only 16.6% kept at least 80% of their loss.

18 min read

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

The lowest legitimate GLP-1 price in 2026 is $149/month, for Foundayo (oral orforglipron) or the Wegovy pill, though top doses cost more. Injectables run $349/month for the Wegovy pen and $299 to $449/month for LillyDirect Zepbound vials. Compounded options remain unsettled.

13 min read

How to Find a GLP-1 Prescriber Near You: The 2026 Patient Guide

There are four legitimate ways to access a GLP-1 in 2026: primary care or obesity-medicine in person, an accredited telehealth platform, NovoCare Pharmacy direct (Wegovy), or LillyDirect Self Pay (Zepbound and Foundayo). Any 'no-prescription' source is illegal.

13 min read

Is Ozempic Available Over the Counter? Honest 2026 Evidence Review

No. Ozempic is a prescription-only drug regulated under 21 CFR Part 503. It cannot be purchased OTC at any US retailer. This article walks the four legitimate Rx pathways, the OTC supplement scam landscape, and FDA / FTC enforcement against fake 'natural Ozempic' products.

11 min read

Can You Lose Weight on Semaglutide Without Exercise? Honest Evidence Review

Yes. STEP-1 reached -14.9% body weight at 68 weeks with diet counseling only — supervised exercise was not the intervention. The catch: without resistance training, roughly 25-40% of the weight you lose comes from lean tissue, not fat.

11 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $129/mo (“starting at” price)

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo (sale price)

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo (prepaid plan rate)

Get started →